Vivoryon Therapeutics Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 14
Employees
  • Stock Symbol
  • VVY
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $16.99
  • (As of Monday Closing)

Vivoryon Therapeutics General Information

Description

Vivoryon Therapeutics NV is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.

Contact Information

Formerly Known As
ProBioTec, Probiodrug
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
AMS
Primary Office
  • Weinbergweg 22
  • 06120 Halle
  • Germany
+49 0345 0000000

Vivoryon Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vivoryon Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.99 $18.32 $3.51 - $25.33 $339M 20M 212K -$0.76

Vivoryon Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 42,456 112,748 16,423 87,327
Revenue 0 0 0 0
EBITDA (13,262) (8,538) (9,057) (11,114)
Net Income (13,607) (8,757) (9,130) (9,032)
Total Assets 42,625 51,372 4,631 12,911
Total Debt 405 455 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vivoryon Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vivoryon Therapeutics‘s full profile, request access.

Request a free trial

Vivoryon Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Ulrich Dauer Chief Executive Officer
Kerstin Kühn-Wache Director, Project Management
Hans-Ulrich Demuth Scientific Advisor and Co-Founder
Ulrich Heiser Senior Director, Medicinal Chemistry
Michael Schaeffer Ph.D Chief Business Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Vivoryon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vivoryon Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vivoryon Therapeutics‘s full profile, request access.

Request a free trial

Vivoryon Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 25-Jun-2007 000000000000000000 Pharmaceuticals
To view Vivoryon Therapeutics’s complete acquisitions history, request access »